急性肺损伤（acute lung injury, ALI）发病率及死亡率均居高不下，是亟待解决的全球公共卫生热点。线粒体功能障碍在ALI的发生发展中占据重要地位，研究表明间充质干细胞（mesenchymal stem cells, MSCs）或其外泌体来源的线粒体移植对ALI具有治疗作用，但外源性线粒体来源及其治疗ALI的机制仍需深入研究。本文针对外源性线粒体来源、线粒体内化方式及线粒体移植对ALI的治疗机制等做一综述，概述外源性线粒体移植治疗急性肺损伤的可行性、潜在价值及其面对的挑战。
The morbidity and mortality of acute lung injury ( ALI ) remain high, which is a global public health hotspot to be solved urgently. Mitochondrial dysfunction plays an important role in the development of ALI. Studies have shown that mesenchymal stem cells (MSCs) or their exosome-derived mitochondria transplantation has a therapeutic effect on ALI, but exogenous mitochondrial sources and their mechanisms for treating ALI still need to be further studied. This article reviews the source of exogenous mitochondria, the way of mitochondrial internalization and the therapeutic mechanism of mitochondrial transplantation on ALI, and summarizes the feasibility, potential value and challenges of exogenous mitochondrial transplantation in the treatment of acute lung injury.
Cited
)
